Trials / Completed
CompletedNCT01632540
Effectiveness of Beclomethasone Dipropionate Nasal Aerosol for Perennial Allergic Rhinitis
Investigation of the Real World Effectiveness of Beclomethasone Dipropionate (BDP) Nasal Aerosol in Perennial Allergic Rhinitis (PAR) Patients
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 824 (actual)
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc. · Industry
- Sex
- All
- Age
- 12 Years
- Healthy volunteers
- Not accepted
Summary
This study will be a prospective observational study of "real world" BDP nasal aerosol users with PAR, with or without seasonal allergic rhinitis (SAR). Subjects will respond to monthly online surveys regarding rhinitis control, concomitant medical conditions, concomitant (non-AR) medications, current AR therapy, and adverse events.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Beclomethasone Dipropionate (BDP) Nasal Aerosol | BDP nasal aerosol 320 mcg/day will be administered to all patients as 2 sprays in each nostril once daily. |
Timeline
- Start date
- 2012-07-01
- Primary completion
- 2013-12-01
- Completion
- 2014-02-01
- First posted
- 2012-07-03
- Last updated
- 2014-04-15
Locations
46 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01632540. Inclusion in this directory is not an endorsement.